First EU-Approved Treatment for Advanced Anal Cancer

For the first time in decades, people facing advanced anal cancer in Europe have an approved treatment designed specifically for them.

The European Commission has greenlit Zynyz combined with chemotherapy drugs carboplatin and paclitaxel as a first-line treatment for advanced squamous cell carcinoma of the anal canal. This aggressive cancer accounts for about 85% of all anal cancer cases, which affect roughly 1 to 2 people per 100,000.

Incyte's Zynyz works as an immunotherapy drug that helps the immune system fight cancer cells. In the POD1UM-303 clinical study, patients receiving the combination lived longer without their disease progressing compared to those getting chemotherapy alone.

The approval matters especially for vulnerable populations. Most anal cancers link to human papillomavirus infection, and the disease appears much more frequently in people living with HIV.

Why This Inspires

This breakthrough shows what happens when pharmaceutical companies focus on rare diseases that major players might overlook. While anal cancer affects relatively few people, those patients deserve effective treatments just as much as anyone else.

Zynyz already reached the market in 2023 for another rare cancer called Merkel cell carcinoma. The company earned $66 million from the drug in 2025, with half that total coming in just the final three months of the year. That acceleration suggests doctors were eager for better options and quickly adopted the treatment once approved.

Before this approval, oncologists sometimes used other immunotherapy drugs off-label, meaning without official approval for this specific cancer. Now patients and doctors have clear guidance backed by clinical trial data.

Bill Meury, Incyte's chief executive, called the approval "an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades."

The FDA approved Zynyz for anal cancer in the United States last year, giving it an even broader green light that includes use as a standalone therapy for patients whose cancer has returned.

Every rare disease patient who gains access to an effective treatment represents hope for others still waiting.